Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Arena Pharma (ARNA) PT Raised to $63 at Credit Suisse
February 27, 2019 8:02 AM ESTCredit Suisse analyst Martin Auster raised the price target on Arena Pharma (NASDAQ: ARNA) to $63.00 (from $61.00) while maintaining a Outperform rating.
... MoreArena Pharma (ARNA) PT Raised to $79 at RBC Capital
February 27, 2019 6:43 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Arena Pharma (NASDAQ: ARNA) to $79.00 (from $70.00) while maintaining a Outperform rating.
Flush with cash, ARNA positions to execute in the clinic in 2019, MacKay comments.
... MoreArena Pharma (ARNA) Tops Q4 Views
February 26, 2019 4:03 PM ESTArena Pharma (NASDAQ: ARNA) reported Q4 EPS of $1.36, $2.12 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $3.6 million.
"In 2018 we delivered the steps necessary to position Arena for long-term, sustainable growth by securing a... More
